News

Get Alerts by Email

May 9, 2018

Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2018 Financial Results

- Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST -

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a...
- Photos 1
May 1, 2018

Galmed Pharmaceuticals to Report First Quarter 2018 Financial Results and Provide Business Update on Wednesday, May 9

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a...
- Photos 1
Apr 3, 2018

Galmed Pharmaceuticals Announces Pricing of $6.0 Million Registered Direct Offering

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a...
- Photos 1
Mar 27, 2018

Galmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on Fibrosis at EASL

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a...
- Photos 1
Mar 13, 2018

Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

Conference Call and Webcast Today at 8:30 a.m. EDT / 5:30 a.m. PDT

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a...
- Photos 1

Show per page